These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 18539919)

  • 1. Glycemic targets and cardiovascular disease.
    Cefalu WT
    N Engl J Med; 2008 Jun; 358(24):2633-5. PubMed ID: 18539919
    [No Abstract]   [Full Text] [Related]  

  • 2. Type 2 diabetes and HbA1c targets.
    Prescrire Int; 2008 Dec; 17(98):254. PubMed ID: 19425272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Individualizing glycemic targets in type 2 diabetes mellitus.
    Aron D; Conlin PR; Hobbs C; Vigersky RA; Pogach L
    Ann Intern Med; 2011 Sep; 155(5):340-1. PubMed ID: 21893635
    [No Abstract]   [Full Text] [Related]  

  • 4. Should patients with type 2 diabetes focus on glycemic control to reduce their cardiovascular risk?
    Montori VM
    Pol Arch Med Wewn; 2008 Sep; 118(9):502-7. PubMed ID: 18846985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Intensive glucose control in type 2 diabetes is beneficial].
    Nilsson PM; Attvall S
    Lakartidningen; 2009 Sep 2-8; 106(36):2198. PubMed ID: 19817174
    [No Abstract]   [Full Text] [Related]  

  • 6. The role of combination therapy in type 2 diabetes in the post-ACCORD era.
    Kuritzky L
    Curr Diab Rep; 2012 Jun; 12(3):227-9. PubMed ID: 22528598
    [No Abstract]   [Full Text] [Related]  

  • 7. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    ; Patel A; MacMahon S; Chalmers J; Neal B; Billot L; Woodward M; Marre M; Cooper M; Glasziou P; Grobbee D; Hamet P; Harrap S; Heller S; Liu L; Mancia G; Mogensen CE; Pan C; Poulter N; Rodgers A; Williams B; Bompoint S; de Galan BE; Joshi R; Travert F
    N Engl J Med; 2008 Jun; 358(24):2560-72. PubMed ID: 18539916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensive glycemic control in the ACCORD and ADVANCE trials.
    Dluhy RG; McMahon GT
    N Engl J Med; 2008 Jun; 358(24):2630-3. PubMed ID: 18539918
    [No Abstract]   [Full Text] [Related]  

  • 9. [Glycemic control and diabetic complications].
    Yamada Y
    Nihon Rinsho; 2005 Jun; 63 Suppl 6():604-8. PubMed ID: 15999778
    [No Abstract]   [Full Text] [Related]  

  • 10. Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide.
    Gerstein HC; Colhoun HM; Dagenais GR; Diaz R; Lakshmanan M; Pais P; Probstfield J; Riddle MC; Rydén L; Xavier D; Atisso CM; Avezum A; Basile J; Chung N; Conget I; Cushman WC; Franek E; Hancu N; Hanefeld M; Holt S; Jansky P; Keltai M; Lanas F; Leiter LA; Lopez-Jaramillo P; Cardona-Munoz EG; Pirags V; Pogosova N; Raubenheimer PJ; Shaw J; Sheu WH; Temelkova-Kurktschiev T;
    Diabetes Obes Metab; 2018 Jan; 20(1):42-49. PubMed ID: 28573765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decrease mortality in type II diabetes mellitus: glycemic and renal function control.
    Borghi C; Ventura F
    J Cardiovasc Med (Hagerstown); 2018 Feb; 19 Suppl 1():e13-e15. PubMed ID: 29538138
    [No Abstract]   [Full Text] [Related]  

  • 12. [Intensive therapy in type 2 diabetes. More damage than benefit?].
    Einecke D
    MMW Fortschr Med; 2008 Jun; 150(26-27):12-4. PubMed ID: 18681224
    [No Abstract]   [Full Text] [Related]  

  • 13. Intensive treatment of hyperglycaemia: ACCORD.
    Klein R
    Lancet; 2010 Aug; 376(9739):391-2. PubMed ID: 20594590
    [No Abstract]   [Full Text] [Related]  

  • 14. Glucose control and vascular complications in veterans with type 2 diabetes.
    Duckworth W; Abraira C; Moritz T; Reda D; Emanuele N; Reaven PD; Zieve FJ; Marks J; Davis SN; Hayward R; Warren SR; Goldman S; McCarren M; Vitek ME; Henderson WG; Huang GD;
    N Engl J Med; 2009 Jan; 360(2):129-39. PubMed ID: 19092145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Intensive blood sugar treatment in type 2 diabetics: no evidence for increased mortality in the ADVANCE study compared with ACCORD study].
    Füchtenbusch M; Hummel M
    MMW Fortschr Med; 2008 Apr; 150(17):42-4. PubMed ID: 18510157
    [No Abstract]   [Full Text] [Related]  

  • 16. [The study of development and progression of long-term complications in type I diabetes].
    Araki E; Matsumura T
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():134-9. PubMed ID: 12386984
    [No Abstract]   [Full Text] [Related]  

  • 17. Aggressive glycemic control might not be best choice for all diabetic patients.
    Mitka M
    JAMA; 2010 Mar; 303(12):1137-8. PubMed ID: 20332394
    [No Abstract]   [Full Text] [Related]  

  • 18. Is Hemoglobin A1c the Right Outcome for Studies of Diabetes?
    Lipska KJ; Krumholz HM
    JAMA; 2017 Mar; 317(10):1017-1018. PubMed ID: 28125758
    [No Abstract]   [Full Text] [Related]  

  • 19. Should we use intensive insulin therapy after oral agent failure in type II diabetes?
    Colwell JA
    Diabetes Care; 1996 Aug; 19(8):896-8. PubMed ID: 8842613
    [No Abstract]   [Full Text] [Related]  

  • 20. [New studies, new strategies, new guidelines: so that diabetic patients will live longer].
    Aumiller J
    MMW Fortschr Med; 2005 Oct; 147(41):4-6. PubMed ID: 16270500
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.